BENTONVILLE, Ark., May 17, 2021 /PRNewswire/ -- Glucose Health, Inc. (OTC: GLUC) ("Company") is pleased to highlight key financial information detailed in its Fiscal 2021 Quarterly Report for the period ending March 31, 2021, posted this morning at OTCMarkets.com.
- Fiscal 2021 Q1 Revenue of $237,465 vs. $82,613 for Q1 2020 – an increase of 187%.
- Fiscal 2021 Gross Profit of $114,871 vs. $39,094 for Q1 2020 – an increase of 194%.
- Total Assets of $1,262,071 ($941,887 cash) at March 31, 2021 vs. Total Assets of $341,321 ($69,151 cash) at March 31, 2020 – an increase of 270%.
- Total Liabilities of $275,922 at March 31, 2021 vs. Total Liabilities of $303,526 at March 31, 2020 – a decrease of 9%.
- Inventory of $264,001 at March 31, 2021 vs $124,776 at March 31, 2020 – an increase of 112%.
Today, Glucose Health, Inc. is also pleased to advise the "substantial doubt as to the Company's ability to continue as a going concern" assumption noted in its financial statements, has been removed. "Substantial doubt" assumptions are present in the financial statements of many companies quoted on OTC Markets and even found in the financial statements of companies listed on stock exchanges such as NASDAQ. The removal of the "substantial doubt" assumption indicates that GLUC has joined the ranks of companies which have achieved the measure of financial stability necessary to meet their obligations and continue in business for the foreseeable future.
About Glucose Health, Inc. (OTC: GLUC)
With a focus on creating delicious beverages nutritionally appropriate1 for the nation's 100+ million2 pre and Type-2 diabetics, Glucose Health, Inc., the manufacturer of GLUCODOWN®, is uniquely positioned among all emerging beverage companies in America. Introduced in the third quarter of 2018, the GLUCODOWN® brand has successfully established itself at the forefront of an entirely new nutritional supplement category – functional, diabetic friendly, beverages. Glucose Health, Inc. is a publicly traded company with the ticker symbol OTC: GLUC.
For more GLUC news visit www.glucosehealthinc.com
Like us on Facebook at www.facebook.com/glucodown
1 For citations visit www.glucodown.com/clinical-data
2 National Diabetes Statistics Review, 2020; Centers for Disease Control and Prevention, Department of Health and Human Services
This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and while Glucose Health, Inc. is not subject to the 1934 Securities and Exchange Act, contains forward-looking statements within the meaning Section 21E of the Securities and Exchange Act of 1934, as amended. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as "expects," "anticipates," "intends," "estimates," "plans," "potential, "possible," "probable, "believes," "seeks," "may, "will, "should," "could" or the negative of such terms or other similar expressions. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in the Company's business. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and the Company undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof.
Contact:
Murray Fleming
Glucose Health, Inc.
[email protected]
(479) 802-3827
SOURCE Glucose Health, Inc.
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article